The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort

Movement Disorders

Volumn 31, Issue 6, 2016, Pages 924-932

  Kang, Un Jung ^a   Goldman, Jennifer G ^b   Alcalay, Roy N ^a   Xie, Tao ^c   Tuite, Paul ^d   Henchcliffe, Claire ^e   Hogarth, Penelope ^f   Amara, Amy W ^g   Frank, Samuel ^h   Rudolph, Alice ⁱ   Casaceli, Cynthia ⁱ   Andrews, Howard ^a   Gwinn, Katrina ^j   Sutherland, Margaret ^j   Kopil, Catherine ^k   Vincent, Lona ^k   Frasier, Mark ^k  

^a New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g University of Alabama at Birmingham   (United States)

^h BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^j NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^k THE MICHAEL J FOX FOUNDATION FOR PARKINSON'S RESEARCH   (United States)

more..

Author keywords

Biomarkers; Cerebrospinal fluid; DNA; Plasma; RNA; Saliva; Urine

Indexed keywords

BIOLOGICAL MARKER; DNA; HEMOGLOBIN; RNA;

AGED; ARTICLE; BLOOD ANALYSIS; BLOOD CELL COUNT; CEREBROSPINAL FLUID ANALYSIS; COGNITION ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE DURATION; DNA DETERMINATION; FEMALE; GAIT DISORDER; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; OBSERVATIONAL STUDY; ONSET AGE; PARASOMNIA; PARKINSON DISEASE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RNA ANALYSIS; SALIVA ANALYSIS; TREATMENT RESPONSE; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE; URINALYSIS; BIOBANK; CLINICAL TRIAL; FACTUAL DATABASE; MIDDLE AGED; MULTICENTER STUDY;

AGED; BIOLOGICAL SPECIMEN BANKS; BIOMARKERS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 84964661212     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26613     Document Type: Article

References (46)

1. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-39.
2. Scherfler C, Schwarz J, Antonini A, et al. Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord 2007;22:1229-1238.
3. Perlmutter JS, Norris SA. Neuroimaging biomarkers for Parkinson disease: facts and fantasy. Ann Neurol 2014;76:769-783..
4. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
5. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG. alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011;10:230-240.
6. Shi M, Bradner J, Hancock AM, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011;69:570-580.
7. Moore HM, Compton CC, Lim MD, Vaught J, Christiansen KN, Alper J. 2009 Biospecimen research network symposium: advancing cancer research through biospecimen science. Cancer Res 2009;69:6770-6772.
8. Parkinson Progression Marker Initiative. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 2011;95:629-635.
9. Adler CH, Beach TG, Hentz JG, et al. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology 2014;83:406-412.
10. Foltynie T, Brayne C, Barker RA. The heterogeneity of idiopathic Parkinson's disease. J Neurol 2002;249:138-145.
11. Lin MK, Farrer MJ. Genetics and genomics of Parkinson's disease. Genome Med 2014;6:48.
12. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci 2003;991:1-14.
13. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
14. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993;50:140-148.
15. Hughes AJ, Daniel SE, Lees AJ. The clinical features of Parkinson's disease in 100 histologically proven cases. Adv Neurol 1993;60:595-599.
16. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992;42:1142-1146.
17. Williams DR, de Silva R, Paviour DC, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 2005;128(Pt 6):1247-1258.
18. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695-699.
19. Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010;75:1062-1069.
20. Tanner CM, Ottman R, Goldman SM, et al. Parkinson disease in twins: an etiologic study. JAMA 1999;281:341-346.
21. Alcalay RN, Caccappolo E, Mejia-Santana H, et al. Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study. Arch Neurol 2010;67:1116-1122.
22. Gan-Or Z, Giladi N, Rozovski U, et al. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 2008;70:2277-2283.
23. Nalls MA, Bras J, Hernandez DG, et al.; International Parkinson's Disease Genomics Consortium (IPDGC); Parkinson's Disease meta-analysis consortium. NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases. Neurobiol Aging 2015;36:1605.e7-12.
24. Nalls MA, Keller MF, Hernandez DG, et al.; Parkinson's Progression Marker Initiative (PPMI) investigators. Baseline genetic associations in the Parkinson's Progression Markers Initiative (PPMI). Mov Disord 2016;31:79-85.
25. Merello M, Nouzeilles MI, Arce GP, Leiguarda R. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis. Mov Disord 2002;17:795-798.
26. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508.
27. Kang UJ, Auinger P; Parkinson Study Group ELLDOPA Investigators. Activity enhances dopaminergic long-duration response in Parkinson disease. Neurology 2012;78:1146-1149.
28. Wang ES, Yao HB, Chen YH, et al. Proteomic analysis of the cerebrospinal fluid of Parkinson's disease patients pre- and post-deep brain stimulation. Cell Physiol Biochem 2013;31:625-637.
29. Bordelon YM, Hays RD, Vassar SD, Diaz N, Bronstein J, Vickrey BG. Medication responsiveness of motor symptoms in a population-based study of Parkinson disease. Parkinson's disease 2011;2011:967839.
30. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129-2170.
31. Stiasny-Kolster K, Mayer G, Schafer S, Moller JC, Heinzel-Gutenbrunner M, Oertel WH. The REM sleep behavior disorder screening questionnaire-a new diagnostic instrument. Mov Disord 2007;22:2386-2393.
32. Fahn S, Elton RL; the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. Florham Park, NJ: Macmillan Healthcare Information; 1987.
33. Rosenthal LS, Drake D, Alcalay RN, et al.; PDBP consortium. The NINDS Parkinson's disease biomarkers program. Movement disorders : official journal of the Movement Disorder Society 2015 Oct 7. doi: 10.1002/mds.26438. [Epub ahead of print].
34. Foulds PG, Diggle P, Mitchell JD, et al. A longitudinal study on α-synuclein in blood plasma as a biomarker for Parkinson's disease. Sci Rep 2013;3:2540.
35. Kang JH, Irwin DJ, Chen-Plotkin AS, et al.; Parkinson's Progression Markers Initiative. Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 2013;70:1277-1287.
36. Kang WY, Yang Q, Jiang XF, et al. Salivary DJ-1 could be an indicator of Parkinson's disease progression. Front Aging Neurosci 2014;6:102.
37. Devic I, Hwang H, Edgar JS, et al. Salivary alpha-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain 2011;134(Pt 7):e178.
38. Fraser KB, Moehle MS, Daher JP, et al. LRRK2 secretion in exosomes is regulated by 14-3-3. Human molecular genetics 2013;22:4988-5000.
39. Shulman LM, Gruber-Baldini AL, Anderson KE, Fishman PS, Reich SG, Weiner WJ. The clinically important difference on the unified Parkinson's disease rating scale. Arch Neurol 2010;67:64-70.
40. Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 1990;40:1529-1534.
41. Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scale. Mov Disord 2013;28:668-670.
42. Chen H, Zhang SM, Hernan MA, Willett WC, Ascherio A. Weight loss in Parkinson's disease. Ann Neurol 2003;53:676-679.
43. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125(Pt 4):861-870.
44. Saito Y, Hamakubo T, Yoshida Y, et al. Preparation and application of monoclonal antibodies against oxidized DJ-1. Significant elevation of oxidized DJ-1 in erythrocytes of early-stage Parkinson disease patients. Neurosci Lett 2009;465:1-5.
45. Margis R, Margis R, Rieder CR. Identification of blood microRNAs associated to Parkinsons disease. J Biotechnol 2011;152:96-101.
46. Dik MG, Deeg DJ, Bouter LM, Corder EH, Kok A, Jonker C. Stroke and apolipoprotein E epsilon4 are independent risk factors for cognitive decline: a population-based study. Stroke 2000;31:2431-2436.